Physician profile
Ronald Willson
NPI 1982601134
$1,173.04
in general payments reported to CMS, 2019-2025
10 companies · $332 in 2025
The $332 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $34.91 · 2021: $18.00 · 2022: $67.62 · 2023: $183 · 2024: $390 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480 · Consulting Fee: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.11 |
| Consulting Fee | $425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $425.00 | 2024-2025 | |
| Abbvie INC. | $338.47 | 2022-2024 | Ozurdex |
| Allergan, INC. | $147.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $82.80 | 2022-2025 | Eylea Hd |
| Bausch & Lomb Americas INC. | $48.38 | 2022-2023 | Xipere |
| Eyepoint US, INC. | $35.89 | 2020-2021 | |
| Alimera Sciences, INC. | $35.66 | 2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $22.18 | 2024 | Izervay |
| Genentech USA, INC. | $20.24 | 2023 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $17.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Willson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.